{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:45:19Z","timestamp":1792464319976,"version":"4.5.0"},"reference-count":569,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.01986","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T11:31:18Z","timestamp":1598614278000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":275,"title":["Phage Display Derived Monoclonal Antibodies: From Bench to Bedside"],"prefix":"10.3389","volume":"11","author":[{"given":"Mohamed A.","family":"Alfaleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hashem O.","family":"Alsaab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad Bakur","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almohanad A.","family":"Alkayyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina L.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Mahler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwar M.","family":"Hashem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc3930","article-title":"Building better monoclonal antibody-based therapeutics","volume":"15","author":"Weiner","year":"2015","journal-title":"Nat Rev Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.4049\/jimmunol.181.9.6213","article-title":"Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates","volume":"181","author":"Schoonbroodt","year":"2008","journal-title":"J Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jconrel.2016.06.040","article-title":"Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation","volume":"244","author":"Zhang","year":"2016","journal-title":"J Control Release."},{"key":"B4","doi-asserted-by":"publisher","first-page":"36031","DOI":"10.1074\/jbc.M805547200","article-title":"Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies","volume":"283","author":"Watanabe","year":"2008","journal-title":"J Biol Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3389\/fmicb.2017.00495","article-title":"Antibody engineering for pursuing a healthier future","volume":"8","author":"Saeed","year":"2017","journal-title":"Front Microbiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1703531","DOI":"10.1080\/19420862.2019.1703531","article-title":"Antibodies to watch in 2020","volume":"12","author":"Kaplon","year":"2020","journal-title":"mAbs."},{"key":"B7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/d41573-019-00049-0","article-title":"Top companies and drugs by sales in 2019","volume":"19","author":"Urquhart","year":"2020","journal-title":"Nat Rev Drug Discov."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/nbt.4305","article-title":"Biopharmaceutical benchmarks 2018","volume":"36","author":"Walsh","year":"2018","journal-title":"Nat Biotechnol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tibtech.2018.05.014","article-title":"The increasingly human and profitable monoclonal antibody market","volume":"37","author":"Grilo","year":"2019","journal-title":"Trends Biotechnol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","article-title":"Antibodies to watch in 2019","volume":"11","author":"Kaplon","year":"2019","journal-title":"mAbs."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e00117-17","DOI":"10.1128\/mBio.00117-17","article-title":"Remembering Emil von Behring: from tetanus treatment to antibody cooperation with phagocytes","volume":"8","author":"Kaufmann","year":"2017","journal-title":"MBio."},{"key":"B13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","article-title":"Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface","volume":"228","author":"Smith","year":"1985","journal-title":"Science."},{"key":"B15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/348552a0","article-title":"Phage antibodies: filamentous phage displaying antibody variable domains","volume":"348","author":"McCafferty","year":"1990","journal-title":"Nature."},{"key":"B16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/349293a0","article-title":"Man-made antibodies","volume":"349","author":"Winter","year":"1991","journal-title":"Nature."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science."},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/d41586-018-06751-0","article-title":"Cancer immunologists scoop medicine Nobel prize","volume":"562","author":"Ledford","year":"2018","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2249.1994.tb06145.x","article-title":"Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6","volume":"98","author":"Legouffe","year":"1994","journal-title":"Clin Exp Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/00000441-200207000-00004","article-title":"Therapeutic applications of monoclonal antibodies","volume":"324","author":"Berger","year":"2002","journal-title":"Am J Med Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0065-2776(08)60640-9","article-title":"Genetically engineered antibody molecules","volume":"44","author":"Morrison","year":"1989","journal-title":"Adv Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/protein\/7.6.805","article-title":"Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues","volume":"7","author":"Studnicka","year":"1994","journal-title":"Protein Eng."},{"key":"B23","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/321522a0","article-title":"Replacing the complementarity-determining regions in a human antibody with those from a mouse","volume":"321","author":"Jones","year":"1986","journal-title":"Nature."},{"key":"B24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/368856a0","article-title":"Antigen-specific human antibodies from mice comprising four distinct genetic modifications","volume":"368","author":"Lonberg","year":"1994","journal-title":"Nature."},{"key":"B25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/ng0297-146","article-title":"Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice","volume":"15","author":"Mendez","year":"1997","journal-title":"Nat Genet."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/nbt1135","article-title":"Human antibodies from transgenic animals","volume":"23","author":"Lonberg","year":"2005","journal-title":"Nat Biotechnol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/0378-1119(88)90495-7","article-title":"Antibody-selectable filamentous FD phage vectors: affinity purification of target genes","volume":"73","author":"Parmley","year":"1988","journal-title":"Gene."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1128\/AAC.00567-12","article-title":"Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites","volume":"56","author":"Huang","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/pharmaceutics11050211","article-title":"Plant\/bacterial virus-based drug discovery, drug delivery, and therapeutics","volume":"11","author":"Sokullu","year":"2019","journal-title":"Pharmaceutics."},{"key":"B30","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/0042-6822(73)90131-1","article-title":"The effect of M13 phage infection upon the F pili of E. coli","volume":"54","author":"O'Callaghan","year":"1973","journal-title":"Virology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/0022-2836(92)90858-H","article-title":"Construction of a microphage variant of filamentous bacteriophage","volume":"228","author":"Specthrie","year":"1992","journal-title":"J Mol Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0378-1119(80)90093-1","article-title":"Nucleotide sequence of the filamentous bacteriophage M13 DNA genome: comparison with phage fd","volume":"11","author":"van Wezenbeek","year":"1980","journal-title":"Gene."},{"key":"B33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21775\/cimb.013.051","article-title":"Filamentous bacteriophage: biology, phage display and nanotechnology applications","volume":"13","author":"Rakonjac","year":"2011","journal-title":"Curr Issues Mol Biol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1006\/jmbi.1999.3465","article-title":"High copy display of large proteins on phage for functional selections","volume":"296","author":"Sidhu","year":"2000","journal-title":"J Mol Biol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817411.ch6","article-title":"Phage and yeast display","volume":"3","author":"Sheehan","year":"2015","journal-title":"Microbiol Spectrum."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4056","DOI":"10.1021\/cr000261r","article-title":"Filamentous phage display in the new millennium","volume":"105","author":"Kehoe","year":"2005","journal-title":"Chem Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0378-1119(91)90244-6","article-title":"A surface expression vector for antibody screening","volume":"104","author":"Breitling","year":"1991","journal-title":"Gene."},{"key":"B38","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/352624a0","article-title":"Making antibody fragments using phage display libraries","volume":"352","author":"Clackson","year":"1991","journal-title":"Nature."},{"key":"B39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/antib8020028","article-title":"David vs. Goliath: the structure, function, and clinical prospects of antibody fragments","volume":"8","author":"Bates","year":"2019","journal-title":"Antibodies."},{"key":"B40","doi-asserted-by":"publisher","first-page":"7978","DOI":"10.1073\/pnas.88.18.7978","article-title":"Assembly of combinatorial antibody libraries on phage surfaces: the gene III site","volume":"88","author":"Barbas","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-61779-968-6_2","article-title":"Introduction to heavy chain antibodies and derived nanobodies","author":"Vincke","year":"2012","journal-title":"Single Domain Antibodies: Methods and Protocols"},{"key":"B42","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ymeth.2018.09.005","article-title":"Structural diversity and flexibility of diabodies","volume":"154","author":"Kwon","year":"2019","journal-title":"Methods."},{"key":"B43","doi-asserted-by":"publisher","first-page":"10832","DOI":"10.1021\/bi00109a004","article-title":"Selecting high-affinity binding proteins by monovalent phage display","volume":"30","author":"Lowman","year":"1991","journal-title":"Biochemistry."},{"key":"B44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/prot.340080405","article-title":"Hormone phage: an enrichment method for variant proteins with altered binding properties","volume":"8","author":"Bass","year":"1990","journal-title":"Proteins."},{"key":"B45","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1389-0344(01)00087-9","article-title":"Engineering M13 for phage display","volume":"18","author":"Sidhu","year":"2001","journal-title":"Biomol Eng."},{"key":"B46","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1021\/cr960065d","article-title":"Phage display","volume":"97","author":"Smith","year":"1997","journal-title":"Chem Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1038\/jid.2013.521","article-title":"Antibody phage display: technique and applications","volume":"134","author":"Hammers","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0378-1119(97)00298-9","article-title":"Filamentous phage infection-mediated gene expression: construction and propagation of the gIII deletion mutant helper phage R408d3","volume":"198","author":"Rakonjac","year":"1997","journal-title":"Gene."},{"key":"B49","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/toxins10060236","article-title":"Basics of antibody phage display technology","volume":"10","author":"Ledsgaard","year":"2018","journal-title":"Toxins (Basel)."},{"key":"B50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/83567","article-title":"A helper phage to improve single-chain antibody presentation in phage display","volume":"19","author":"Rondot","year":"2001","journal-title":"Nat Biotechnol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/0022-2836(91)90498-U","article-title":"By-passing immunization. Human antibodies from V-gene libraries displayed on phage","volume":"222","author":"Marks","year":"1991","journal-title":"J Mol Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1073\/pnas.88.10.4363","article-title":"Linkage of recognition and replication functions by assembling combinatorial antibody Fab libraries along phage surfaces","volume":"88","author":"Kang","year":"1991","journal-title":"Proc Natl Acad Sci USA."},{"key":"B53","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3390\/molecules16010412","article-title":"Phage display for the generation of antibodies for proteome research, diagnostics and therapy","volume":"16","author":"Schirrmann","year":"2011","journal-title":"Molecules."},{"key":"B54","doi-asserted-by":"publisher","first-page":"B818","DOI":"10.1149\/2.057210jes","article-title":"Blocking agent optimization for nonspecific binding on phage based magnetoelastic biosensors","volume":"159","author":"Shen","year":"2012","journal-title":"J Electrochem Soc."},{"key":"B55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ab.2004.09.048","article-title":"The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies","volume":"336","author":"Menendez","year":"2005","journal-title":"Anal Biochem."},{"key":"B56","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0076-6879(93)17065-D","article-title":"Libraries of peptides and proteins displayed on filamentous phage","volume":"217","author":"Smith","year":"1993","journal-title":"Methods Enzymol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/nprot.2012.132","article-title":"The use of phage display to generate conformation-sensor recombinant antibodies","volume":"7","author":"Haque","year":"2012","journal-title":"Nat Protoc."},{"key":"B58","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0022-1759(95)00231-6","article-title":"Retrieval of human antibodies from phage-display libraries using enzymatic cleavage","volume":"189","author":"Ward","year":"1996","journal-title":"J Immunol Methods."},{"key":"B59","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1359-0278(98)00044-3","article-title":"Proteolytic selection for protein folding using filamentous bacteriophages","volume":"3","author":"Kristensen","year":"1998","journal-title":"Fold Des."},{"key":"B60","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.biotechadv.2010.07.004","article-title":"Phage display: concept, innovations, applications and future","volume":"28","author":"Pande","year":"2010","journal-title":"Biotechnol Adv."},{"key":"B61","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jim.2010.02.001","article-title":"A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies","volume":"354","author":"Jones","year":"2010","journal-title":"J Immunol Methods."},{"key":"B62","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/978-1-59745-554-1_16","article-title":"Affinity maturation by phage display","volume":"525","author":"Thie","year":"2009","journal-title":"Methods Mol Biol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1021\/ac902283n","article-title":"Two-step in vitro antibody affinity maturation enables estradiol-17beta assays with more than 10-fold higher sensitivity","volume":"82","author":"Kobayashi","year":"2010","journal-title":"Anal Chem."},{"key":"B64","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jmb.2007.08.005","article-title":"High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries","volume":"373","author":"Fellouse","year":"2007","journal-title":"J Mol Biol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1016\/j.jmb.2015.06.018","article-title":"A new versatile immobilization tag based on the ultra high affinity and reversibility of the calmodulin-calmodulin binding peptide interaction","volume":"427","author":"Mukherjee","year":"2015","journal-title":"J Mol Biol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2016","journal-title":"Nat Rev Drug Discov."},{"key":"B67","doi-asserted-by":"publisher","first-page":"14808","DOI":"10.1073\/pnas.0803103105","article-title":"Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity","volume":"105","author":"Sarkar","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B68","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1146\/annurev.biophys.28.1.319","article-title":"Membrane protein folding and stability: physical principles","volume":"28","author":"White","year":"1999","journal-title":"Annu Rev Biophys Biomol Struct."},{"key":"B69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/08820139709048914","article-title":"Adsorption-induced antigenic changes and their significance in ELISA and immunological disorders","volume":"26","author":"Butler","year":"1997","journal-title":"Immunol Invest."},{"key":"B70","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(92)90066-3","article-title":"The physical and functional behavior of capture antibodies adsorbed on polystyrene","volume":"150","author":"Butler","year":"1992","journal-title":"J Immunol Methods."},{"key":"B71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","article-title":"Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line","volume":"65","author":"Nagy","year":"2005","journal-title":"Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jmb.2008.03.072","article-title":"An entirely cell-based system to generate single-chain antibodies against cell surface receptors","volume":"379","author":"Lipes","year":"2008","journal-title":"J Mol Biol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"26240","DOI":"10.1038\/srep26240","article-title":"Targeting membrane proteins for antibody discovery using phage display","volume":"6","author":"Jones","year":"2016","journal-title":"Sci Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/antib6030010","article-title":"Strategies for selecting membrane protein-specific antibodies using phage display with cell-based panning","volume":"6","author":"Alfaleh","year":"2017","journal-title":"Antibodies."},{"key":"B75","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/antib8010015","article-title":"Canine CD117-specific antibodies with diverse binding properties isolated from a phage display library using cell-based biopanning","volume":"8","author":"Alfaleh","year":"2019","journal-title":"Antibodies."},{"key":"B76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/978-1-60327-569-9_18","article-title":"Biopanning of phage displayed peptide libraries for the isolation of cell-specific ligands","volume":"504","author":"McGuire","year":"2009","journal-title":"Methods Mol Biol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jim.2007.11.008","article-title":"Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells","volume":"330","author":"Siva","year":"2008","journal-title":"J Immunol Methods."},{"key":"B78","doi-asserted-by":"publisher","first-page":"7724","DOI":"10.1158\/0008-5472.CAN-05-4441","article-title":"Selection of tumor-binding ligands in cancer patients with phage display libraries","volume":"66","author":"Krag","year":"2006","journal-title":"Cancer Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.3390\/ijms13055420","article-title":"Antibody phage display libraries: contributions to oncology","volume":"13","author":"Dantas-Barbosa","year":"2012","journal-title":"Int J Mol Sci."},{"key":"B80","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0958-1669(97)80075-4","article-title":"Phage display of combinatorial antibody libraries","volume":"8","author":"Rader","year":"1997","journal-title":"Curr Opin Biotechnol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1038\/nprot.2007.455","article-title":"Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules","volume":"2","author":"Eisenhardt","year":"2007","journal-title":"Nat Protoc."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1096\/fj.04-1513fje","article-title":"Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaIIbbeta3 designed by subtractive selection from naive human phage libraries","volume":"18","author":"Schwarz","year":"2004","journal-title":"FASEB J."},{"key":"B83","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1161\/01.RES.0000232317.84122.0c","article-title":"Conformation-specific blockade of the integrin GPIIb\/IIIa: a novel antiplatelet strategy that selectively targets activated platelets","volume":"99","author":"Schwarz","year":"2006","journal-title":"Circ Res."},{"key":"B84","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1182\/blood-2006-03-007179","article-title":"Generation of activation-specific human anti-alphaMbeta2 single-chain antibodies as potential diagnostic tools and therapeutic agents","volume":"109","author":"Eisenhardt","year":"2007","journal-title":"Blood."},{"key":"B85","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2012.12.010","article-title":"Generating conformation-specific synthetic antibodies to trap proteins in selected functional states","volume":"60","author":"Paduch","year":"2013","journal-title":"Methods."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1111\/j.1582-4934.2010.00896.x","article-title":"Microselection\u2013affinity selecting antibodies against a single rare cell in a heterogeneous population","volume":"14","author":"Sorensen","year":"2010","journal-title":"J Cell Mol Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nprot.2011.311","article-title":"Selection of antibodies against a single rare cell present in a heterogeneous population using phage display","volume":"6","author":"Sorensen","year":"2011","journal-title":"Nat Protoc."},{"key":"B88","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/biom10030421","article-title":"Machine learning-guided prediction of antigen-reactive in silico clonotypes based on changes in clonal abundance through bio-panning","volume":"10","author":"Yoo","year":"2020","journal-title":"Biomolecules."},{"key":"B89","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/nbt.2492","article-title":"High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire","volume":"31","author":"DeKosky","year":"2013","journal-title":"Nat Biotechnol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"9137","DOI":"10.1039\/C8CS00523K","article-title":"Third generation antibody discovery methods: in silico rational design","volume":"47","author":"Sormanni","year":"2018","journal-title":"Chem Soc Rev."},{"key":"B91","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/19420862.2019.1571878","article-title":"High-throughput retrieval of physical DNA for NGS-identifiable clones in phage display library","volume":"11","author":"Noh","year":"2019","journal-title":"MAbs."},{"key":"B92","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1039\/C9LC00978G","article-title":"Retooling phage display with electrohydrodynamic nanomixing and nanopore sequencing","volume":"19","author":"Raftery","year":"2019","journal-title":"Lab Chip."},{"key":"B93","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/s41587-020-0512-5","article-title":"Developing therapeutic monoclonal antibodies at pandemic pace","volume":"38","author":"Kelley","year":"2020","journal-title":"Nat Biotechnol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1002\/j.1460-2075.1994.tb06626.x","article-title":"Isolation of high affinity human antibodies directly from large synthetic repertoires","volume":"13","author":"Griffiths","year":"1994","journal-title":"EMBO J."},{"key":"B95","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1021\/jp911706q","article-title":"Prediction of aggregation prone regions of therapeutic proteins","volume":"114","author":"Chennamsetty","year":"2010","journal-title":"J Phys Chem B."},{"key":"B96","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1073\/pnas.1616408114","article-title":"Biophysical properties of the clinical-stage antibody landscape","volume":"114","author":"Jain","year":"2017","journal-title":"Proc Natl Acad Sci USA."},{"key":"B97","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.molimm.2019.06.012","article-title":"Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies","volume":"112","author":"Lecerf","year":"2019","journal-title":"Mol Immunol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4161\/19420862.2014.985544","article-title":"Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection","volume":"7","author":"Lavoisier","year":"2015","journal-title":"mAbs."},{"key":"B99","doi-asserted-by":"publisher","first-page":"38644","DOI":"10.1038\/srep38644","article-title":"Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo","volume":"6","author":"Dobson","year":"2016","journal-title":"Sci Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s10529-013-1445-6","article-title":"Biopharmaceutical liquid formulation: a review of the science of protein stability and solubility in aqueous environments","volume":"36","author":"Bye","year":"2014","journal-title":"Biotechnol Lett."},{"key":"B101","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejpb.2017.06.029","article-title":"High-concentration protein formulations: how high is high?","volume":"119","author":"Garidel","year":"2017","journal-title":"Eur J Pharm Biopharm."},{"key":"B102","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.1002\/jps.21327","article-title":"Measuring and increasing protein solubility","volume":"97","author":"Trevino","year":"2008","journal-title":"J Pharm Sci."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/jps.22350","article-title":"Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies","volume":"100","author":"Gibson","year":"2011","journal-title":"J Pharm Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"8200","DOI":"10.1038\/s41598-017-07800-w","article-title":"Rapid and accurate in silico solubility screening of a monoclonal antibody library","volume":"7","author":"Sormanni","year":"2017","journal-title":"Sci Rep."},{"key":"B105","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/19420862.2015.1017695","article-title":"Boosting antibody developability through rational sequence optimization","volume":"7","author":"Seeliger","year":"2015","journal-title":"mAbs."},{"key":"B106","doi-asserted-by":"publisher","first-page":"11937","DOI":"10.1073\/pnas.0904191106","article-title":"Design of therapeutic proteins with enhanced stability","volume":"106","author":"Chennamsetty","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B107","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-12-386483-3.00004-5","article-title":"Aggregation, stability, and formulation of human antibody therapeutics","volume":"84","author":"Lowe","year":"2011","journal-title":"Adv Protein Chem Struct Biol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1146\/annurev-chembioeng-062011-081052","article-title":"Engineering aggregation-resistant antibodies","volume":"3","author":"Perchiacca","year":"2012","journal-title":"Annu Rev Chem Biomol Eng."},{"key":"B109","doi-asserted-by":"publisher","first-page":"E501","DOI":"10.1208\/aapsj080359","article-title":"Effects of protein aggregates: an immunologic perspective","volume":"8","author":"Rosenberg","year":"2006","journal-title":"AAPS J."},{"key":"B110","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/antib5030019","article-title":"Antibody aggregation: insights from sequence and structure","volume":"5","author":"Li","year":"2016","journal-title":"Antibodies."},{"key":"B111","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4161\/mabs.19869","article-title":"Solubility evaluation of murine hybridoma antibodies","volume":"4","author":"Spencer","year":"2012","journal-title":"mAbs."},{"key":"B112","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/prot.25685","article-title":"Phage display derived therapeutic antibodies have enriched aliphatic content: insights for developability issues","volume":"87","author":"Kaleli","year":"2019","journal-title":"Proteins."},{"key":"B113","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.4049\/jimmunol.162.4.2162","article-title":"Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(1 \u2192 6) dextran antibody","volume":"162","author":"Coloma","year":"1999","journal-title":"J Immunol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ab.2005.11.012","article-title":"Impact of variable domain glycosylation on antibody clearance: an LC\/MS characterization","volume":"349","author":"Huang","year":"2006","journal-title":"Anal Biochem."},{"key":"B115","doi-asserted-by":"publisher","first-page":"753","DOI":"10.4161\/mabs.22189","article-title":"A strategy for risk mitigation of antibodies with fast clearance","volume":"4","author":"Hotzel","year":"2012","journal-title":"mAbs."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3389\/fimmu.2017.01751","article-title":"Progress and challenges in the design and clinical development of antibodies for cancer therapy","volume":"8","author":"Almagro","year":"2017","journal-title":"Front Immunol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ymeth.2012.03.014","article-title":"Protein selection using yeast surface display","volume":"60","author":"Gera","year":"2013","journal-title":"Methods."},{"key":"B118","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.abb.2012.03.009","article-title":"Engineering antibodies by yeast display","volume":"526","author":"Boder","year":"2012","journal-title":"Arch Biochem Biophys."},{"key":"B119","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nbt0697-553","article-title":"Yeast surface display for screening combinatorial polypeptide libraries","volume":"15","author":"Boder","year":"1997","journal-title":"Nat Biotechnol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-60327-302-2_8","article-title":"Display and selection of scFv antibodies on HEK-293T cells","volume":"562","author":"Ho","year":"2009","journal-title":"Methods Mol Biol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/978-1-59745-554-1_18","article-title":"Mammalian cell display for antibody engineering","volume":"525","author":"Ho","year":"2009","journal-title":"Methods Mol Biol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"9637","DOI":"10.1073\/pnas.0603653103","article-title":"Isolation of anti-CD22 Fv with high affinity by Fv display on human cells","volume":"103","author":"Ho","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B123","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jim.2007.07.007","article-title":"Whole IgG surface display on mammalian cells: application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies","volume":"327","author":"Akamatsu","year":"2007","journal-title":"J Immunol Methods."},{"key":"B124","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4161\/mabs.2.5.12970","article-title":"Development of a novel mammalian cell surface antibody display platform","volume":"2","author":"Zhou","year":"2010","journal-title":"mAbs."},{"key":"B125","doi-asserted-by":"publisher","first-page":"14336","DOI":"10.1073\/pnas.0805942105","article-title":"Isolation of human monoclonal antibodies by mammalian cell display","volume":"105","author":"Beerli","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B126","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/protein\/gzy004","article-title":"Identification of high affinity HER2 binding antibodies using CHO Fab surface display","volume":"31","author":"Nguyen","year":"2018","journal-title":"Protein Eng Des Sel."},{"key":"B127","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/19420862.2019.1618673","article-title":"A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing","volume":"11","author":"Parthiban","year":"2019","journal-title":"mAbs."},{"key":"B128","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/19420862.2019.1571879","article-title":"ALTHEA Gold Libraries\u2122: antibody libraries for therapeutic antibody discovery","volume":"11","author":"Valadon","year":"2019","journal-title":"mAbs."},{"key":"B129","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/19420862.2018.1556082","article-title":"In vitro and in silico assessment of the developability of a designed monoclonal antibody library","volume":"11","author":"Wolf","year":"2019","journal-title":"mAbs."},{"key":"B130","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4161\/mabs.24218","article-title":"A fully synthetic human Fab antibody library based on fixed VH\/VL framework pairings with favorable biophysical properties","volume":"5","author":"Tiller","year":"2013","journal-title":"mAbs."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1002\/jps.24430","article-title":"Developability assessment during the selection of novel therapeutic antibodies","volume":"104","author":"Jarasch","year":"2015","journal-title":"J Pharm Sci."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1787121","DOI":"10.1080\/19420862.2020.1787121","article-title":"Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain","volume":"12","author":"Bauer","year":"2020","journal-title":"mAbs."},{"key":"B133","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1073\/pnas.1810576116","article-title":"Five computational developability guidelines for therapeutic antibody profiling","volume":"116","author":"Raybould","year":"2019","journal-title":"Proc Natl Acad Sci USA."},{"key":"B134","doi-asserted-by":"publisher","first-page":"R254","DOI":"10.1186\/gb-2007-8-11-r254","article-title":"Application of phage display to high throughput antibody generation and characterization","volume":"8","author":"Schofield","year":"2007","journal-title":"Genome Biol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jim.2011.08.005","article-title":"Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays","volume":"373","author":"Chan","year":"2011","journal-title":"J Immunol Methods."},{"key":"B136","doi-asserted-by":"publisher","first-page":"e75212","DOI":"10.1371\/journal.pone.0075212","article-title":"A novel helper phage enabling construction of genome-scale ORF-enriched phage display libraries","volume":"8","author":"Gupta","year":"2013","journal-title":"PLoS ONE."},{"key":"B137","doi-asserted-by":"publisher","first-page":"11146","DOI":"10.1073\/pnas.95.19.11146","article-title":"Unexpected frameshifts from gene to expressed protein in a phage-displayed peptide library","volume":"95","author":"C\u00e1rcamo","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B138","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.pep.2008.01.002","article-title":"A step-wise approach significantly enhances protein yield of a rationally-designed agonist antibody fragment in E. coli","volume":"59","author":"Lin","year":"2008","journal-title":"Protein Expr Purif"},{"key":"B139","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/bfgp\/1.2.189","article-title":"Concepts in antibody phage display","volume":"1","author":"Carmen","year":"2002","journal-title":"Brief Funct Genomic Proteomic."},{"key":"B140","doi-asserted-by":"publisher","first-page":"3796","DOI":"10.1038\/s41598-017-03957-6","article-title":"Effect of DNA sequence of Fab fragment on yield characteristics and cell growth of E. coli","volume":"7","author":"Kulmala","year":"2017","journal-title":"Sci Rep"},{"key":"B141","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/0378-1119(96)00337-X","article-title":"Inclusion of an upstream transcriptional terminator in phage display vectors abolishes background expression of toxic fusions with coat protein g3p","volume":"178","author":"Krebber","year":"1996","journal-title":"Gene."},{"key":"B142","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/BF02993480","article-title":"The production and application of single-chain antibody fragments","volume":"48","author":"Blazek","year":"2003","journal-title":"Folia Microbiol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jviromet.2003.09.020","article-title":"Generation and characterization of single-chain antibody fragments specific against transmembrane envelope glycoprotein gp46 of maedi-visna virus","volume":"115","author":"Blazek","year":"2004","journal-title":"J Virol Methods."},{"key":"B144","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-7447-4_1","article-title":"Construction of human immune and naive scFv libraries","volume-title":"Phage Display: Methods and Protocols","author":"K\u00fcgler","year":"2018"},{"key":"B145","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1365-2249.1997.4161316.x","article-title":"Isolation of human anti-c-erbB-2 Fabs from a lymph node-derived phage display library","volume":"109","author":"Clark","year":"1997","journal-title":"Clin Exp Immunol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0165-5728(97)00199-9","article-title":"Selection of recombinant anti-HuD Fab fragments from a phage display antibody library of a lung cancer patient with paraneoplastic encephalomyelitis","volume":"82","author":"Graus","year":"1998","journal-title":"J Neuroimmunol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/S1380-2933(97)00013-4","article-title":"Evaluation of different lymphoid tissue sources for the construction of human immunoglobulin gene libraries","volume":"3","author":"Yip","year":"1997","journal-title":"Immunotechnology."},{"key":"B148","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3892\/ijmm.14.4.729","article-title":"Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines","volume":"14","author":"Rothe","year":"2004","journal-title":"Int J Mol Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.3748\/wjg.v10.i18.2619","article-title":"Production of a human single-chain variable fragment antibody against esophageal carcinoma","volume":"10","author":"Xu","year":"2004","journal-title":"World J Gastroenterol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jim.2004.04.007","article-title":"Antibodies from phage antibody libraries","volume":"290","author":"Bradbury","year":"2004","journal-title":"J Immunol Methods."},{"key":"B151","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1691\/ph.2009.8352","article-title":"Rapid isolation of intrabody candidates by using an optimized non-immune phage antibody library","volume":"64","author":"Nagano","year":"2009","journal-title":"Pharmazie."},{"key":"B152","doi-asserted-by":"publisher","first-page":"655","DOI":"10.14348\/molcells.2017.0106","article-title":"Generation, diversity determination, and application to antibody selection of a human naive Fab library","volume":"40","author":"Kim","year":"2017","journal-title":"Mol Cells."},{"key":"B153","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12896-015-0125-0","article-title":"Generation and analysis of the improved human HAL9\/10 antibody phage display libraries","volume":"15","author":"K\u00fcgler","year":"2015","journal-title":"BMC Biotechnol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jim.2013.02.010","article-title":"Discovery of diverse and functional antibodies from large human repertoire antibody libraries","volume":"391","author":"Schwimmer","year":"2013","journal-title":"J Immunol Methods."},{"key":"B155","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/antib8030044","article-title":"Phage display libraries for antibody therapeutic discovery and development","volume":"8","author":"Almagro","year":"2019","journal-title":"Antibodies."},{"key":"B156","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/pro.2874","article-title":"The diversity of H3 loops determines the antigen-binding tendencies of antibody CDR loops","volume":"25","author":"Tsuchiya","year":"2016","journal-title":"Protein Sci."},{"key":"B157","doi-asserted-by":"publisher","first-page":"302","DOI":"10.3389\/fimmu.2013.00302","article-title":"The structural basis of antibody-antigen recognition","volume":"4","author":"Sela-Culang","year":"2013","journal-title":"Front Immunol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1096\/fasebj.9.1.7821752","article-title":"Identification of specificity-determining residues in antibodies","volume":"9","author":"Padlan","year":"1995","journal-title":"FASEB J."},{"key":"B159","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/protein\/gzt027","article-title":"The indistinguishability of epitopes from protein surface is explained by the distinct binding preferences of each of the six antigen-binding loops","volume":"26","author":"Kunik","year":"2013","journal-title":"Protein Eng Des Sel."},{"key":"B160","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1006\/jmbi.1997.1354","article-title":"Standard conformations for the canonical structures of immunoglobulins","volume":"273","author":"Al-Lazikani","year":"1997","journal-title":"J Mol Biol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.4049\/jimmunol.1201493","article-title":"A systematic comparison of free and bound antibodies reveals binding-related conformational changes","volume":"189","author":"Sela-Culang","year":"2012","journal-title":"J Immunol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/342877a0","article-title":"Conformations of immunoglobulin hypervariable regions","volume":"342","author":"Chothia","year":"1989","journal-title":"Nature."},{"key":"B163","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/0022-2836(87)90412-8","article-title":"Canonical structures for the hypervariable regions of immunoglobulins","volume":"196","author":"Chothia","year":"1987","journal-title":"J Mol Biol."},{"key":"B164","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0014-5793(99)00821-2","article-title":"H3-rules: identification of CDR-H3 structures in antibodies","volume":"455","author":"Shirai","year":"1999","journal-title":"FEBS Lett."},{"key":"B165","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.ijbiomac.2019.06.006","article-title":"Phage display antibody libraries: a robust approach for generation of recombinant human monoclonal antibodies","volume":"135","author":"Kumar","year":"2019","journal-title":"Int J Biol Macromol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S1074-7613(00)00006-6","article-title":"Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities","volume":"13","author":"Xu","year":"2000","journal-title":"Immunity."},{"key":"B167","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/mps2010017","article-title":"Efficient construction and effective screening of synthetic domain antibody libraries","volume":"2","author":"Solemani Zadeh","year":"2019","journal-title":"Methods Protoc."},{"key":"B168","doi-asserted-by":"publisher","first-page":"21769","DOI":"10.1074\/jbc.273.34.21769","article-title":"Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel","volume":"273","author":"Pini","year":"1998","journal-title":"J Biol Chem."},{"key":"B169","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1073\/pnas.89.10.4457","article-title":"Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem","volume":"89","author":"Barbas","year":"1992","journal-title":"Proc Natl Acad Sci USA."},{"key":"B170","doi-asserted-by":"publisher","first-page":"38194","DOI":"10.1074\/jbc.M303164200","article-title":"Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3","volume":"278","author":"Rauchenberger","year":"2003","journal-title":"J Biol Chem."},{"key":"B171","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4161\/mabs.27240","article-title":"Drugs derived from phage display: from candidate identification to clinical practice","volume":"6","author":"Nixon","year":"2014","journal-title":"mAbs."},{"key":"B172","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/19420862.2016.1212149","article-title":"Phage display-derived human antibodies in clinical development and therapy","volume":"8","author":"Frenzel","year":"2016","journal-title":"mAbs."},{"key":"B173","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/nbt0396-309","article-title":"Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library","volume":"14","author":"Vaughan","year":"1996","journal-title":"Nat Biotechnol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1093\/protein\/gzn058","article-title":"Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens","volume":"22","author":"Lloyd","year":"2009","journal-title":"Protein Eng Des Sel."},{"key":"B175","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jim.2006.04.002","article-title":"Affinity maturation of phage display antibody populations using ribosome display","volume":"313","author":"Groves","year":"2006","journal-title":"J Immunol Methods."},{"key":"B176","doi-asserted-by":"publisher","first-page":"18218","DOI":"10.1074\/jbc.274.26.18218","article-title":"A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies","volume":"274","author":"de Haard","year":"1999","journal-title":"J Biol Chem."},{"key":"B177","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1006\/jmbi.1999.3444","article-title":"Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides","volume":"296","author":"Knappik","year":"2000","journal-title":"J Mol Biol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.jmb.2007.12.018","article-title":"The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies","volume":"376","author":"Rothe","year":"2008","journal-title":"J Mol Biol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jmb.2011.08.012","article-title":"HuCAL PLATINUM, a synthetic Fab library optimized for sequence diversity and superior performance in mammalian expression systems","volume":"413","author":"Prassler","year":"2011","journal-title":"J Mol Biol."},{"key":"B180","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nbt0994-899","article-title":"Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen","volume":"12","author":"Jespers","year":"1994","journal-title":"Biotechnology."},{"key":"B181","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1136\/annrheumdis-2011-201244","article-title":"Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease","volume":"72","author":"Burmester","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B182","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/03946320140270S103","article-title":"Adalimumab in the treatment of immune-mediated diseases","volume":"27","author":"Lapadula","year":"2014","journal-title":"Int J Immunopathol Pharmacol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/bjd.17919","article-title":"Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials","volume":"181","author":"Jemec","year":"2019","journal-title":"Br J Dermatol."},{"key":"B184","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.disamonth.2018.06.001","article-title":"Biologics for the primary care physician: review and treatment of psoriasis","volume":"65","author":"Schadler","year":"2019","journal-title":"Dis Mon."},{"key":"B185","doi-asserted-by":"publisher","first-page":"1623847","DOI":"10.1155\/2019\/1623847","article-title":"Adalimumab accounts for long-term control of noninfectious uveitis also in the absence of concomitant DMARD treatment: a multicenter retrospective study","volume":"2019","author":"Bitossi","year":"2019","journal-title":"Mediators Inflamm."},{"key":"B186","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/PL00006684","article-title":"Anti-self antibodies selected from a human IgD heavy chain repertoire: a novel approach to generate therapeutic human antibodies against tumor-associated differentiation antigens","volume":"50","author":"Raum","year":"2001","journal-title":"Cancer Immunol Immunother."},{"key":"B187","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/sj.bjc.6602310","article-title":"Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines","volume":"92","author":"Prang","year":"2005","journal-title":"Br J Cancer."},{"key":"B188","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/annonc\/mdr625","article-title":"Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer","volume":"23","author":"Schmidt","year":"2012","journal-title":"Ann Oncol."},{"key":"B189","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/annonc\/mdp314","article-title":"An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer","volume":"21","author":"Schmidt","year":"2010","journal-title":"Ann Oncol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1159\/000318055","article-title":"Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy","volume":"85","author":"Marschner","year":"2010","journal-title":"Urol Int."},{"key":"B191","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/nm736","article-title":"Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells","volume":"8","author":"Nagy","year":"2002","journal-title":"Nat Med."},{"key":"B192","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1158\/0008-5472.CAN-05-1200","article-title":"The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic\/severe combined immunodeficient mice","volume":"66","author":"Carlo-Stella","year":"2006","journal-title":"Cancer Res."},{"key":"B193","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/0008-5472.CAN-06-3744","article-title":"IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3","volume":"67","author":"Carlo-Stella","year":"2007","journal-title":"Cancer Res."},{"key":"B194","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","article-title":"Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect","volume":"13","author":"Golfier","year":"2014","journal-title":"Mol Cancer Ther."},{"key":"B195","doi-asserted-by":"publisher","first-page":"34103","DOI":"10.18632\/oncotarget.26135","article-title":"Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models","volume":"9","author":"Quanz","year":"2018","journal-title":"Oncotarget."},{"key":"B196","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-018-0775-7","article-title":"Safety and tolerability of antibody-drug conjugates in cancer","volume":"42","author":"Wolska-Washer","year":"2019","journal-title":"Drug Saf."},{"key":"B197","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1073\/pnas.95.2.669","article-title":"Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity","volume":"95","author":"Chowdhury","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"B198","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun."},{"key":"B199","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin Cancer Res."},{"key":"B200","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.2147\/OTT.S145105","article-title":"Amatuximab and novel agents targeting mesothelin for solid tumors","volume":"10","author":"Baldo","year":"2017","journal-title":"Onco Targets Ther."},{"key":"B201","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature."},{"key":"B202","author":"Irving","year":"2012","journal-title":"Anti-pd-l1 Antibodies, Compositions and Articles of Manufacture"},{"key":"B203","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/21645515.2017.1403694","article-title":"Product review on the Anti-PD-L1 antibody atezolizumab","volume":"14","author":"Shah","year":"2018","journal-title":"Hum Vaccin Immunother."},{"key":"B204","doi-asserted-by":"publisher","first-page":"S100","DOI":"10.21037\/tlcr.2019.11.23","article-title":"Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives","volume":"9","author":"Gray","year":"2020","journal-title":"Transl Lung Cancer Res."},{"key":"B205","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","article-title":"Atezolizumab: a PD-L1-blocking antibody for bladder cancer","volume":"23","author":"Inman","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B206","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/17512433.2017.1356717","article-title":"Atezolizumab for the treatment of non-small cell lung cancer","volume":"10","author":"Santini","year":"2017","journal-title":"Expert Rev Clin Pharmacol."},{"key":"B207","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/s00120-016-0188-0","article-title":"First-line treatment for advanced renal cell carcinoma: a phase 3, open-label, randomized study of atezolizumab (anti-PD-L1-Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma (IMmotion)\u2013AN 37\/15 der AUO","volume":"55","author":"Rexer","year":"2016","journal-title":"Urologe A."},{"key":"B208","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/14737140.2020.1732211","article-title":"Atezolizumab for the treatment of breast cancer","volume":"20","author":"Reddy","year":"2020","journal-title":"Expert Rev Anticancer Ther."},{"key":"B209","doi-asserted-by":"publisher","first-page":"6538","DOI":"10.2174\/1381612822666160923113714","article-title":"Therapeutic antibodies by phage display","volume":"22","author":"Shim","year":"2016","journal-title":"Curr Pharm Des."},{"key":"B210","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.2217\/fon-2018-0070","article-title":"Avelumab (anti-PD-L1) in platinum-resistant\/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design","volume":"14","author":"Pujade-Lauraine","year":"2018","journal-title":"Future Oncol."},{"key":"B211","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol."},{"key":"B212","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol."},{"key":"B213","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer."},{"key":"B214","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11523-018-0571-4","article-title":"Avelumab: a review in metastatic merkel cell carcinoma","volume":"13","author":"Shirley","year":"2018","journal-title":"Target Oncol."},{"key":"B215","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med."},{"key":"B216","doi-asserted-by":"publisher","first-page":"1756287218823485","DOI":"10.1177\/1756287218823485","article-title":"A review of avelumab in locally advanced and metastatic bladder cancer","volume":"11","author":"Rao","year":"2019","journal-title":"Ther Adv Urol."},{"key":"B217","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum."},{"key":"B218","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nbt.2076","article-title":"The discovery and development of belimumab: the anti-BLyS-lupus connection","volume":"30","author":"Stohl","year":"2012","journal-title":"Nat Biotechnol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1177\/0961203319869468","article-title":"Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus","volume":"28","author":"Benitez","year":"2019","journal-title":"Lupus."},{"key":"B220","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B221","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1124\/jpet.106.110734","article-title":"A potent human anti-eotaxin1 antibody, CAT-213: isolation by phage display and in vitro and in vivo efficacy","volume":"319","author":"Main","year":"2006","journal-title":"J Pharmacol Exp Ther."},{"key":"B222","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1177\/1945892418787132","article-title":"Biologics in chronic rhinosinusitis: an update and thoughts for future directions","volume":"32","author":"Smith","year":"2018","journal-title":"Am J Rhinol Allergy."},{"key":"B223","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/1756283X14558193","article-title":"Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases","volume":"8","author":"Amiot","year":"2015","journal-title":"Therap Adv Gastroenterol."},{"key":"B224","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3389\/fimmu.2019.00978","article-title":"Current clinical trials in pemphigus and pemphigoid","volume":"10","author":"Izumi","year":"2019","journal-title":"Front Immunol."},{"key":"B225","doi-asserted-by":"publisher","first-page":"e0195305","DOI":"10.1371\/journal.pone.0195305","article-title":"Healthcare utilisation prior to the diagnosis of inflammatory bowel diseases and the influence of livestock exposure: a longitudinal case-control study","volume":"13","author":"van der Star","year":"2018","journal-title":"PLoS ONE."},{"key":"B226","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.13042","article-title":"Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals","volume":"20","author":"Garito","year":"2018","journal-title":"Diabetes Obes Metab."},{"key":"B228","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol."},{"key":"B229","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study","volume":"65","author":"Rooks","year":"2017","journal-title":"J Am Geriatr Soc."},{"key":"B230","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/jcsm.12205","article-title":"Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy","volume":"8","author":"Rooks","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle."},{"key":"B231","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1080\/14712598.2016.1208168","article-title":"Novel therapeutic options for cachexia and sarcopenia","volume":"16","author":"Molfino","year":"2016","journal-title":"Expert Opin Biol Ther."},{"key":"B232","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.pep.2007.05.017","article-title":"Codon engineering for improved antibody expression in mammalian cells","volume":"55","author":"Carton","year":"2007","journal-title":"Protein Expr Purif."},{"key":"B233","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11523-014-0320-2","article-title":"Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study","volume":"10","author":"Brana","year":"2015","journal-title":"Target Oncol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s00280-013-2099-8","article-title":"A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors","volume":"71","author":"Sandhu","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"key":"B235","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10637-012-9869-8","article-title":"Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer","volume":"31","author":"Pienta","year":"2013","journal-title":"Invest New Drugs."},{"key":"B236","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1183\/13993003.01558-2014","article-title":"CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J."},{"key":"B237","doi-asserted-by":"publisher","first-page":"5549s","DOI":"10.1158\/1078-0432.CCR-07-1109","article-title":"IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor","volume":"13","author":"Rowinsky","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B238","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1093\/annonc\/mdx534","article-title":"Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508)","volume":"28","author":"Argiris","year":"2017","journal-title":"Ann Oncol."},{"key":"B239","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jhep.2013.09.008","article-title":"A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma","volume":"60","author":"Abou-Alfa","year":"2014","journal-title":"J Hepatol."},{"key":"B240","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/pbc.24605","article-title":"Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group","volume":"61","author":"Weigel","year":"2014","journal-title":"Pediatr Blood Cancer."},{"key":"B241","doi-asserted-by":"publisher","first-page":"9062","DOI":"10.1128\/JVI.79.14.9062-9068.2005","article-title":"Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants","volume":"79","author":"Bakker","year":"2005","journal-title":"J Virol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1002\/eji.200526134","article-title":"The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries","volume":"35","author":"Kramer","year":"2005","journal-title":"Eur J Immunol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/19420862.2015.1115166","article-title":"Development and characterization of human monoclonal antibodies that neutralize multiple TGFbeta isoforms","volume":"8","author":"Bedinger","year":"2016","journal-title":"mAbs."},{"key":"B244","doi-asserted-by":"publisher","first-page":"e1257453","DOI":"10.1080\/2162402X.2016.1257453","article-title":"Novel TGF-beta inhibitors ready for prime time in onco-immunology","volume":"6","author":"de Gramont","year":"2017","journal-title":"Oncoimmunology."},{"key":"B245","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.ekir.2017.03.011","article-title":"A phase 2, double-blind, placebo-controlled, randomized study of fresolimumab in patients with steroid-resistant primary focal segmental glomerulosclerosis","volume":"2","author":"Vincenti","year":"2017","journal-title":"Kidney Int Rep."},{"key":"B246","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1172\/JCI77958","article-title":"Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients","volume":"125","author":"Rice","year":"2015","journal-title":"J Clin Invest."},{"key":"B247","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1158\/1078-0432.CCR-17-3322","article-title":"Focal irradiation and systemic TGFbeta blockade in metastatic breast cancer","volume":"24","author":"Formenti","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B248","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res."},{"key":"B249","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B250","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1002\/art.38617","article-title":"A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B251","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B252","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/jdv.15287","article-title":"Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J)","volume":"33","author":"Okubo","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B253","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/sj.bjc.6602487","article-title":"HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo","volume":"92","author":"Pukac","year":"2005","journal-title":"Br J Cancer"},{"key":"B254","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1182\/blood.V116.21.5031.5031","article-title":"A multicenter randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with bortezomib in patients with relapsed\/refractory multiple myeloma (MM)","volume":"116","author":"Belch","year":"2010","journal-title":"Blood."},{"key":"B255","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/sj.bjc.6605507","article-title":"Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer","volume":"102","author":"Trarbach","year":"2010","journal-title":"Br J Cancer."},{"key":"B256","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cllc.2013.12.005","article-title":"Phase II trial of mapatumumab, a fully human agonist monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer","volume":"15","author":"von Pawel","year":"2014","journal-title":"Clin Lung Cancer."},{"key":"B257","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.bjc.6605987","article-title":"A phase 1b\/2 trial of mapatumumab in patients with relapsed\/refractory non-Hodgkin's lymphoma","volume":"103","author":"Younes","year":"2010","journal-title":"Br J Cancer."},{"key":"B258","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1136\/ard.2010.146225","article-title":"Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study","volume":"70","author":"Burmester","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B259","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/art.40323","article-title":"A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis","volume":"70","author":"Weinblatt","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B260","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s40265-019-01192-z","article-title":"Targeting granulocyte-monocyte colony-stimulating factor signaling in rheumatoid arthritis: future prospects","volume":"79","author":"Crotti","year":"2019","journal-title":"Drugs."},{"key":"B261","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11912-020-00934-7","article-title":"COVID-19 and cancer: a comprehensive review","volume":"22","author":"Gosain","year":"2020","journal-title":"Curr Oncol Rep."},{"key":"B262","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B263","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00280-019-03875-6","article-title":"Moxetumomab pasudotox-tdfk for relapsed\/refractory hairy cell leukemia: a review of clinical considerations","volume":"84","author":"Nobre","year":"2019","journal-title":"Cancer Chemother Pharmacol."},{"key":"B264","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia."},{"key":"B265","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/protein\/gzl031","article-title":"A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration","volume":"19","author":"Krinner","year":"2006","journal-title":"Protein Eng Des Sel."},{"key":"B266","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/j.molimm.2006.03.020","article-title":"A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF","volume":"44","author":"Krinner","year":"2007","journal-title":"Mol Immunol."},{"key":"B267","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13075-019-1879-x","article-title":"Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial","volume":"21","author":"Taylor","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B268","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1007\/s40674-018-0095-1","article-title":"Novel therapeutic targets in axial spondyloarthritis","volume":"4","author":"Worth","year":"2018","journal-title":"Curr Treatm Opt Rheumatol."},{"key":"B269","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br J Dermatol."},{"key":"B270","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.str.2007.11.009","article-title":"Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8","volume":"16","author":"Li","year":"2008","journal-title":"Structure."},{"key":"B271","first-page":"163","article-title":"Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy","volume":"64","author":"Liu","year":"2004","journal-title":"Cancer Research."},{"key":"B272","doi-asserted-by":"publisher","first-page":"8008","DOI":"10.1200\/jco.2014.32.15_suppl.8008","article-title":"A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8\/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC)","volume":"32","author":"Thatcher","year":"2014","journal-title":"J Clin Oncol."},{"key":"B273","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2217\/fon-2018-0594","article-title":"Necitumumab for the treatment of advanced non-small-cell lung cancer","volume":"15","author":"Diaz-Serrano","year":"2019","journal-title":"Future Oncol."},{"key":"B274","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/bjc.2015.480","article-title":"Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer","volume":"114","author":"Elez","year":"2016","journal-title":"Br J Cancer."},{"key":"B275","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-09-2425","article-title":"A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies","volume":"16","author":"Kuenen","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B276","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1124\/jpet.111.183483","article-title":"Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration","volume":"339","author":"Pepinsky","year":"2011","journal-title":"J Pharmacol Exp Ther."},{"key":"B277","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S1474-4422(19)30137-1","article-title":"Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial","volume":"18","author":"Cadavid","year":"2019","journal-title":"Lancet Neurol."},{"key":"B278","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"Lancet Neurol."},{"key":"B279","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/19420862.2015.1045168","article-title":"TTAC-0001, a human monoclonal antibody targeting VEGFR-2\/KDR, blocks tumor angiogenesis","volume":"7","author":"Lee","year":"2015","journal-title":"mAbs."},{"key":"B280","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-662-04605-0_2","article-title":"Construction of scFv fragments from hybridoma or spleen cells by PCR assembly","volume-title":"Antibody Engineering.","author":"Burmester","year":"2001"},{"key":"B281","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1007\/s10637-017-0463-y","article-title":"Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors","volume":"35","author":"Lee","year":"2017","journal-title":"Invest New Drugs."},{"key":"B282","doi-asserted-by":"publisher","first-page":"e13522","DOI":"10.1200\/JCO.2017.35.15_suppl.e13522","article-title":"A multicenter, 3-arm, open-label, phase IIa clinical trial to evaluate the safety and efficacy of tanibirumab (VEGFR2 mAb), in patients with recurrent glioblastoma (GBM)","volume":"35","author":"Cher","year":"2017","journal-title":"J Clin Oncol."},{"key":"B283","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1007\/s00262-012-1237-1","article-title":"Targeting of 4\u20131BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity","volume":"61","author":"Fisher","year":"2012","journal-title":"Cancer Immunol Immunother."},{"key":"B284","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.1158\/1078-0432.CCR-17-1243","article-title":"Phase Ib study of utomilumab (PF-05082566), a 4\u20131BB\/CD137 agonist, in combination with pembrolizumab (MK-3475) in patients with advanced solid tumors","volume":"23","author":"Tolcher","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B285","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1200\/EDBK_200715","article-title":"Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer","volume":"38","author":"Pegram","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"B286","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3389\/fonc.2018.00351","article-title":"Cancer immunotherapy in diffuse large B-cell lymphoma","volume":"8","author":"Zhang","year":"2018","journal-title":"Front Oncol."},{"key":"B287","doi-asserted-by":"publisher","first-page":"2040620719841581","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther Adv Hematol."},{"key":"B288","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/d41573-019-00051-6","article-title":"Non-Hodgkin lymphoma therapy landscape","volume":"18","author":"Chaudhari","year":"2019","journal-title":"Nat Rev Drug Discov."},{"key":"B289","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1535-7163.MCT-08-1171","article-title":"AMG 479, a fully human anti\u2013insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells","volume":"8","author":"Beltran","year":"2009","journal-title":"Mol Cancer Ther."},{"key":"B290","doi-asserted-by":"publisher","first-page":"e55135","DOI":"10.1371\/journal.pone.0055135","article-title":"Epitope-specific mechanisms of IGF1R inhibition by ganitumab","volume":"8","author":"Calzone","year":"2013","journal-title":"PLoS ONE."},{"key":"B291","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/annonc\/mdt057","article-title":"A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer","volume":"24","author":"Cohn","year":"2013","journal-title":"Ann Oncol."},{"key":"B292","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1093\/annonc\/mdv027","article-title":"A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial","volume":"26","author":"Fuchs","year":"2015","journal-title":"Ann Oncol."},{"key":"B293","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.18139.1","article-title":"Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force","volume":"8","author":"Bailey","year":"2019","journal-title":"F1000Research."},{"key":"B294","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1158\/1538-7445.AM2014-1022","article-title":"Abstract 1022: development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2)","volume":"74","author":"Bready","year":"2014","journal-title":"Cancer Res."},{"key":"B295","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-15-2145","article-title":"A phase I, first-in-human study of AMG 780, an angiopoietin-1 and\u22122 inhibitor, in patients with advanced solid tumors","volume":"22","author":"Dowlati","year":"2016","journal-title":"Clin Cancer Res."},{"key":"B296","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature."},{"key":"B297","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","article-title":"Properties, production, and applications of camelid single-domain antibody fragments","volume":"77","author":"Harmsen","year":"2007","journal-title":"Appl Microbiol Biotechnol."},{"key":"B298","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1182\/blood-2010-11-317859","article-title":"Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs","volume":"118","author":"Ulrichts","year":"2011","journal-title":"Blood."},{"key":"B299","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","article-title":"Caplacizumab: first global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs."},{"key":"B300","doi-asserted-by":"publisher","first-page":"LBA-1","DOI":"10.1182\/blood.V130.Suppl_1.LBA-1.LBA-1","article-title":"Results of the randomized, double-blind, placebo-controlled, phase 3 Hercules study of caplacizumab in patients with acquired thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood."},{"key":"B301","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijc.1634","article-title":"Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy","volume":"97","author":"Lu","year":"2002","journal-title":"Int J Cancer."},{"key":"B302","doi-asserted-by":"publisher","first-page":"43496","DOI":"10.1074\/jbc.M307742200","article-title":"Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity","volume":"278","author":"Lu","year":"2003","journal-title":"J Biol Chem."},{"key":"B303","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/annonc\/mdv144","article-title":"Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors","volume":"26","author":"Chiorean","year":"2015","journal-title":"Ann Oncol."},{"key":"B304","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1016\/j.cllc.2018.06.005","article-title":"RELEVENT trial: phase II trial of ramucirumab, carboplatin, and paclitaxel in previously untreated thymic carcinoma\/B3 thymoma with area of carcinoma","volume":"19","author":"Imbimbo","year":"2018","journal-title":"Clin Lung Cancer."},{"key":"B305","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.SABCS13-S5-04","article-title":"Primary results of ROSE\/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","volume":"33","author":"Mackey","year":"2014","journal-title":"J Clin Oncol."},{"key":"B306","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1016\/S0140-6736(17)32365-6","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial","volume":"390","author":"Petrylak","year":"2017","journal-title":"Lancet."},{"key":"B307","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14712598.2019.1656715","article-title":"Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer","volume":"19","author":"Khan","year":"2019","journal-title":"Expert Opin Biol Ther."},{"key":"B308","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet."},{"key":"B309","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1177\/1758834016635888","article-title":"Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy","volume":"8","author":"Verdaguer","year":"2016","journal-title":"Ther Adv Med Oncol."},{"key":"B310","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"B311","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res."},{"key":"B312","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0969-2126(98)00116-6","article-title":"VEGF and the Fab fragment of a humanized neutralizing antibody: crystal structure of the complex at 2.4 \u00c5 resolution and mutational analysis of the interface","volume":"6","author":"Muller","year":"1998","journal-title":"Structure."},{"key":"B313","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1006\/jmbi.1999.3192","article-title":"Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen","volume":"293","author":"Chen","year":"1999","journal-title":"J Mol Biol."},{"key":"B314","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.oret.2018.06.005","article-title":"Ranibizumab induces regression of diabetic retinopathy in most patients at high risk of progression to proliferative diabetic retinopathy","volume":"2","author":"Wykoff","year":"2018","journal-title":"Ophthalmol Retina."},{"key":"B315","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41433-018-0300-3","article-title":"Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service","volume":"33","author":"Gale","year":"2019","journal-title":"Eye."},{"key":"B316","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology."},{"key":"B317","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s12325-017-0548-1","article-title":"Ranibizumab in the treatment of diabetic macular edema: a review of the current status, unmet needs, and emerging challenges","volume":"34","author":"Dervenis","year":"2017","journal-title":"Adv Ther."},{"key":"B318","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41433-018-0192-2","article-title":"Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan","volume":"32","author":"Ohno-Matsui","year":"2018","journal-title":"Eye."},{"key":"B319","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40123-017-0083-9","article-title":"A review of ranibizumab for the treatment of diabetic retinopathy","volume":"6","author":"Stewart","year":"2017","journal-title":"Ophthalmol Ther."},{"key":"B320","doi-asserted-by":"publisher","first-page":"8106","DOI":"10.1200\/jco.2007.25.18_suppl.8106","article-title":"Fully human antibody MOR202 against CD38 for the treatment of multiple myeloma and other blood-borne malignancies","volume":"25","author":"Tesar","year":"2007","journal-title":"J Clin Oncol."},{"key":"B321","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1182\/blood.V126.23.3035.3035","article-title":"Phase I\/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma","volume":"126","author":"Raab","year":"2015","journal-title":"Blood."},{"key":"B322","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1182\/blood.V99.5.1659","article-title":"Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix","volume":"99","author":"Carnemolla","year":"2002","journal-title":"Blood."},{"key":"B323","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1016\/j.ejca.2010.07.033","article-title":"The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma","volume":"46","author":"Johannsen","year":"2010","journal-title":"Eur J Cancer."},{"key":"B324","doi-asserted-by":"publisher","first-page":"100001","DOI":"10.1016\/j.cytox.2018.100001","article-title":"The challenges and molecular approaches surrounding interleukin-2-based therapeutics in cancer","volume":"1","author":"Tang","year":"2019","journal-title":"Cytokine."},{"key":"B325","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1182\/blood-2003-04-1039","article-title":"Selective targeted delivery of TNFalpha to tumor blood vessels","volume":"102","author":"Borsi","year":"2003","journal-title":"Blood."},{"key":"B326","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/bjc.2013.421","article-title":"The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity","volume":"109","author":"Hemmerle","year":"2013","journal-title":"Br J Cancer."},{"key":"B327","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.nbt.2019.04.002","article-title":"Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation","volume":"52","author":"Murer","year":"2019","journal-title":"Nat Biotechnol."},{"key":"B328","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/ijc.10662","article-title":"Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin","volume":"102","author":"Borsi","year":"2002","journal-title":"Int J Cancer."},{"key":"B329","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2326-6066.CIR-13-0007","article-title":"Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study","volume":"1","author":"Poli","year":"2013","journal-title":"Cancer Immunol Res."},{"key":"B330","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2967\/jnumed.111.101006","article-title":"Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies","volume":"53","author":"Erba","year":"2012","journal-title":"J Nucl Med."},{"key":"B331","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4161\/mabs.1.6.10195","article-title":"Raxibacumab","volume":"1","author":"Mazumdar","year":"2009","journal-title":"mAbs."},{"key":"B332","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3389\/fmicb.2015.01320","article-title":"Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration Animal Rule","volume":"6","author":"Tsai","year":"2015","journal-title":"Front Microbiol."},{"key":"B333","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.molimm.2008.07.013","article-title":"In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification","volume":"46","author":"Steidl","year":"2008","journal-title":"Mol Immunol."},{"key":"B334","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/annrheumdis-2019-eular.6035","article-title":"OP0228 GSK3196165 an investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIb study of patients with rheumatoid arthritis (RA)","volume":"78","author":"Buckley","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B335","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1759720X17752036","article-title":"Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-\u03b1 in rheumatoid arthritis: focus on mavrilimumab","volume":"10","author":"Cook","year":"2018","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B336","doi-asserted-by":"publisher","first-page":"ra31","DOI":"10.1126\/scisignal.2000352","article-title":"Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor\u2013PI3K axis","volume":"2","author":"Schoeberl","year":"2009","journal-title":"Sci Signal."},{"key":"B337","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ab.2006.01.043","article-title":"High-throughput affinity ranking of antibodies using surface plasmon resonance microarrays","volume":"351","author":"Wassaf","year":"2006","journal-title":"Anal Biochem."},{"key":"B338","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1158\/1535-7163.MCT-15-0169","article-title":"Seribantumab, an anti-ERBB3 antibody, delays the onset of resistance and restores sensitivity to letrozole in an estrogen receptor-positive breast cancer model","volume":"14","author":"Curley","year":"2015","journal-title":"Mol Cancer Ther."},{"key":"B339","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1634\/theoncologist.2018-0695","article-title":"Randomized phase II trial of seribantumab in combination with erlotinib in patients with EGFR wild-type non-small cell lung cancer","volume":"24","author":"Sequist","year":"2019","journal-title":"Oncologist."},{"key":"B340","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1073\/pnas.0602341103","article-title":"Probing a protein-protein interaction by in vitro evolution","volume":"103","author":"Thom","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B341","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1476-5381.2011.01659.x","article-title":"Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma","volume":"166","author":"May","year":"2012","journal-title":"Br J Pharmacol."},{"key":"B342","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2213-2600(18)30184-X","article-title":"Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials","volume":"6","author":"Panettieri","year":"2018","journal-title":"Lancet Respir Med."},{"key":"B343","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B344","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1158\/1535-7163.MCT-13-1023","article-title":"Effector-mediated eradication of precursor B acute lymphoblastic leukemia with a novel Fc-engineered monoclonal antibody targeting the BAFF-R","volume":"13","author":"Parameswaran","year":"2014","journal-title":"Mol Cancer Ther."},{"key":"B345","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/bit.20151","article-title":"Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity","volume":"87","author":"Yamane-Ohnuki","year":"2004","journal-title":"Biotechnol Bioeng."},{"key":"B346","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1182\/bloodadvances.2018025684","article-title":"Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib","volume":"3","author":"McWilliams","year":"2019","journal-title":"Blood Adv."},{"key":"B347","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sj\u00f6gren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"D\u00f6rner","year":"2019","journal-title":"Ann Rheum Dis."},{"key":"B348","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1212\/NXI.0000000000000405","article-title":"B-cell-targeted therapies in relapsing forms of MS","volume":"4","author":"Dubey","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"B349","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1158\/1078-0432.CCR-05-2804","article-title":"Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C","volume":"12","author":"Brack","year":"2006","journal-title":"Clin Cancer Res."},{"key":"B350","doi-asserted-by":"publisher","first-page":"6515","DOI":"10.1158\/1078-0432.CCR-07-5041","article-title":"Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy","volume":"14","author":"M\u00e5rlind","year":"2008","journal-title":"Clin Cancer Res."},{"key":"B351","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0076-6879(00)26071-0","article-title":"Design and use of phage display libraries for the selection of antibodies and enzymes","volume":"326","author":"Viti","year":"2000","journal-title":"Methods Enzymol."},{"key":"B352","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1158\/2326-6066.CIR-14-0179","article-title":"Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation","volume":"3","author":"Schliemann","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B353","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.3390\/cancers6021180","article-title":"Systemic therapy for merkel cell carcinoma: what's on the horizon?","volume":"6","author":"Rabinowits","year":"2014","journal-title":"Cancers (Basel)."},{"key":"B354","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/CPAA.S49231","article-title":"Immunocytokines: a review of molecules in clinical development for cancer therapy","volume":"5","author":"List","year":"2013","journal-title":"Clin Pharmacol."},{"key":"B355","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1158\/1535-7163.MCT-13-0598","article-title":"Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin","volume":"13","author":"Friedbichler","year":"2014","journal-title":"Mol Cancer Ther."},{"key":"B356","doi-asserted-by":"publisher","first-page":"S1187","DOI":"10.1016\/j.jtho.2016.11.1672","article-title":"P3.02b-005 phase Ib trial of afatinib and BI 836845 in advanced NSCLC: dose escalation and safety results: topic: EGFR biomarkers","volume":"12","author":"Park","year":"2017","journal-title":"J Thorac Oncol."},{"key":"B357","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1200\/jco.2014.32.15_suppl.2622","article-title":"Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors","volume":"32","author":"Rihawi","year":"2014","journal-title":"J Clin Oncol."},{"key":"B358","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11523-017-0514-5","article-title":"Insulin-like growth factor (IGF) pathway targeting in cancer: role of the IGF axis and opportunities for future combination studies","volume":"12","author":"Simpson","year":"2017","journal-title":"Target Oncol."},{"key":"B359","doi-asserted-by":"publisher","first-page":"TPS1103","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS1103","article-title":"XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)\/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement","volume":"37","author":"Schmid","year":"2019","journal-title":"J Clin Oncol."},{"key":"B360","author":"Kneissel","year":"2011","journal-title":"Compositions and Methods for Use for Antibodies Against Sclerostin"},{"key":"B361","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J Bone Miner Res."},{"key":"B362","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1172\/JCI83731","article-title":"Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia","volume":"127","author":"Seefried","year":"2017","journal-title":"J Clin Invest."},{"key":"B363","doi-asserted-by":"publisher","first-page":"6217286","DOI":"10.1155\/2016\/6217286","article-title":"Sclerostin antibody therapy for the treatment of osteoporosis: clinical prospects and challenges","volume":"2016","author":"MacNabb","year":"2016","journal-title":"J Osteoporos."},{"key":"B364","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1242\/jcs.01138","article-title":"Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C","volume":"117","author":"Persaud","year":"2004","journal-title":"J Cell Sci."},{"key":"B365","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00280-016-3134-3","article-title":"Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856\/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer","volume":"78","author":"Saif","year":"2016","journal-title":"Cancer Chemother Pharmacol."},{"key":"B366","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1158\/0008-5472.CAN-16-0180","article-title":"Preclinical efficacy of the auristatin-based antibody\u2013drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors","volume":"76","author":"Sommer","year":"2016","journal-title":"Cancer Res."},{"key":"B367","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/78458","article-title":"Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries","volume":"18","author":"S\u00f6derlind","year":"2000","journal-title":"Nat Biotechnol."},{"key":"B368","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1158\/1538-7445.AM2014-4766","article-title":"Abstract 4766: pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC","volume":"74","author":"Schatz","year":"2014","journal-title":"Cancer Res."},{"key":"B369","author":"Wang","year":"2018","journal-title":"Monoclonal Antibodies Against Tissue Factor Pathway Inhibitor (TFPI)"},{"key":"B370","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.1182\/blood.V126.23.3513.3513","article-title":"Characterization of a high-affinity fully human IgG2 antibody against tissue factor pathway inhibitor as a bypass agent for the treatment of hemophilia","volume":"126","author":"Bauzon","year":"2015","journal-title":"Blood."},{"key":"B371","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1182\/blood.V126.23.3496.3496","article-title":"Antibody engineering of anti-TFPI bypass therapeutic BAY 1093884: isotype selection and sequence optimization","volume":"126","author":"Paz","year":"2015","journal-title":"Blood."},{"key":"B372","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/bloodadvances.2019000849","article-title":"Laboratory monitoring of hemophilia A treatments: new challenges","volume":"4","author":"Lenting","year":"2020","journal-title":"Blood Adv."},{"key":"B373","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/rth2.12186","article-title":"BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics","volume":"3","author":"Thomas","year":"2019","journal-title":"Res Pract Thromb Haemost."},{"key":"B374","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J Mol Biol."},{"key":"B375","doi-asserted-by":"publisher","first-page":"7425","DOI":"10.1021\/acs.jmedchem.8b00173","article-title":"Factor XIa inhibitors as new anticoagulants","volume":"61","author":"Quan","year":"2018","journal-title":"J Med Chem."},{"key":"B376","author":"Almagro Juan","year":"2013","journal-title":"Il-17a Antibodies"},{"key":"B377","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3899\/jrheum.161238","article-title":"CNTO6785, a fully human antiinterleukin 17 monoclonal antibody, in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomized, placebo-controlled, phase II, dose-ranging study","volume":"45","author":"Mease","year":"2018","journal-title":"J Rheumatol."},{"key":"B378","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","article-title":"A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease","volume":"14","author":"Eich","year":"2017","journal-title":"COPD."},{"key":"B379","author":"Cunningham","year":"2013","journal-title":"Toll-like Receptor 3 Antagonists"},{"key":"B380","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.jaci.2017.06.027","article-title":"Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: a randomized controlled study","volume":"141","author":"Silkoff","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B381","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"JAMA Dermatol."},{"key":"B382","first-page":"515","article-title":"ABT-874, a fully human monoclonal anti-IL-12\/IL-23 antibody for the potential treatment of autoimmune diseases","volume":"9","author":"Ding","year":"2008","journal-title":"Curr Opin Investig Drugs."},{"key":"B383","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/1352458510384496","article-title":"A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and\u221223 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis","volume":"17","author":"Vollmer","year":"2011","journal-title":"Mult Scler."},{"key":"B384","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1365-2133.2011.10419.x","article-title":"Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Strober","year":"2011","journal-title":"Br J Dermatol."},{"key":"B385","first-page":"3987","article-title":"BHQ880, a novel anti-DKK1 neutralizing antibody, inhibits tumor-induced osteolytic bone disease","volume":"68","author":"Ettenberg","year":"2008","journal-title":"Cancer Research."},{"key":"B386","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1182\/blood.V114.22.750.750","article-title":"A phase I\/II study of BHQ880, a novel osteoblat activating, anti-DKK1 human monoclonal antibody, in relapsed and refractory multiple myeloma (MM) patients treated with zoledronic acid (Zol) and anti-myeloma therapy (MM Tx)","volume":"114","author":"Padmanabhan","year":"2009","journal-title":"Blood."},{"key":"B387","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood.V120.21.331.331","article-title":"Early evidence of anabolic bone activity of BHQ880, a fully human anti-DKK1 neutralizing antibody: results of a phase 2 study in previously untreated patients with smoldering multiple myeloma at risk for progression","volume":"120","author":"Munshi","year":"2012","journal-title":"Blood."},{"key":"B388","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2015.03.005","article-title":"Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo","volume":"27","author":"Roghanian","year":"2015","journal-title":"Cancer Cell."},{"key":"B389","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fimmu.2019.00481","article-title":"Targeting the antibody checkpoints to enhance cancer immunotherapy-focus on FcgammaRIIB","volume":"10","author":"Teige","year":"2019","journal-title":"Front Immunol."},{"key":"B390","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/ijc.23408","article-title":"A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo","volume":"122","author":"Villa","year":"2008","journal-title":"Int J Cancer"},{"key":"B391","doi-asserted-by":"publisher","first-page":"603.2","DOI":"10.1136\/annrheumdis-2018-eular.5550","article-title":"FRI0118 Dekavil (F8IL10)\u2013update on the results of clinical trials investigating the immunocytokine in patients with rheumatoid arthritis","volume":"77","author":"Galeazzi","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B392","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/1380-2933(95)00007-0","article-title":"In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library","volume":"1","author":"Schier","year":"1995","journal-title":"Immunotechnology."},{"key":"B393","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.abb.2012.05.007","article-title":"Selection and characterization of cell binding and internalizing phage antibodies","volume":"526","author":"Zhou","year":"2012","journal-title":"Arch Biochem Biophys."},{"key":"B394","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12885-016-2385-z","article-title":"HERMIONE: a randomized phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-na\u00efve, HER2-positive, locally advanced\/metastatic breast cancer","volume":"16","author":"Miller","year":"2016","journal-title":"BMC Cancer."},{"key":"B395","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s41416-018-0235-2","article-title":"Safety and pharmacokinetics of MM-302, a HER2-targeted antibody\u2013liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study","volume":"119","author":"Munster","year":"2018","journal-title":"Br J Cancer."},{"key":"B396","author":"Benson","year":"2016","journal-title":"Human Anti-il-23 Antibodies, Compositions, Methods and Uses"},{"key":"B397","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/prot.24554","article-title":"Antibody modeling assessment II. Structures and models","volume":"82","author":"Teplyakov","year":"2014","journal-title":"Proteins."},{"key":"B398","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40265-017-0800-7","article-title":"Guselkumab: first global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs."},{"key":"B399","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B400","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamadermatol.2017.5937","article-title":"Efficacy and safety of guselkumab, an anti\u2013interleukin 23 monoclonal antibody, for palmoplantar pustulosis: a randomized clinical trial","volume":"154","author":"Terui","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B401","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1535-7163.MCT-16-0474","article-title":"Preclinical antitumor efficacy of BAY 1129980\u2014a novel auristatin-based anti-C4.4A (LYPD3) antibody\u2013drug conjugate for the treatment of non\u2013small cell lung cancer","volume":"16","author":"Willuda","year":"2017","journal-title":"Mol Cancer Ther."},{"key":"B402","doi-asserted-by":"publisher","first-page":"23596","DOI":"10.1074\/jbc.M114.569061","article-title":"Inhibition of plasma kallikrein by a highly specific active site blocking antibody","volume":"289","author":"Kenniston","year":"2014","journal-title":"J Biol Chem."},{"key":"B403","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1001\/jama.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA."},{"key":"B404","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s40265-018-0987-2","article-title":"Lanadelumab: first global approval","volume":"78","author":"Syed","year":"2018","journal-title":"Drugs."},{"key":"B405","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1200\/JCO.2012.44.1055","article-title":"Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors","volume":"30","author":"Merchant","year":"2012","journal-title":"J Clin Oncol."},{"key":"B406","doi-asserted-by":"publisher","first-page":"14006","DOI":"10.1200\/jco.2007.25.18_suppl.14006","article-title":"A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI","volume":"25","author":"Sikic","year":"2007","journal-title":"J Clin Oncol."},{"key":"B407","doi-asserted-by":"publisher","first-page":"e1208875","DOI":"10.1080\/2162402X.2016.1208875","article-title":"Targeting CD73 in the tumor microenvironment with MEDI9447","volume":"5","author":"Hay","year":"2016","journal-title":"OncoImmunology."},{"key":"B408","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2018.36.15_suppl.4123","article-title":"Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc)","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol."},{"key":"B409","doi-asserted-by":"publisher","first-page":"S930","DOI":"10.1016\/j.jtho.2018.08.1730","article-title":"P3.04\u201323 phase 1b\/2 study to evaluate novel combinations with oleclumab (MEDI9447) in previously treated advanced EGFRm NSCLC","volume":"13","author":"Rizvi","year":"2018","journal-title":"J Thorac Oncol."},{"key":"B410","doi-asserted-by":"publisher","first-page":"OT3-01","DOI":"10.1158\/1538-7445.SABCS18-OT3-01-01","article-title":"Abstract OT3\u201301-01: BEGONIA: phase Ib\/II open-label, platform study of safety and efficacy of durvalumab, paclitaxel and other novel oncology therapy agents as first-line (1L) therapy in patients with metastatic triple negative breast cancer (mTNBC)","volume":"79","author":"Schmid","year":"2019","journal-title":"Cancer Res."},{"key":"B411","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1158\/1078-0432.CCR-14-2808","article-title":"Targeting notch signaling with a Notch2\/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency","volume":"21","author":"Yen","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B412","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s10637-018-0714-6","article-title":"A phase 1 dose escalation and expansion study of tarextumab (OMP-59R5) in patients with solid tumors","volume":"37","author":"Smith","year":"2019","journal-title":"Invest New Drugs."},{"key":"B413","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1200\/JCO.2017.35.4_suppl.279","article-title":"Results of a randomized phase II trial of an anti-notch 2\/3, tarextumab (OMP-59R5, TRXT, anti-Notch2\/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC)","volume":"35","author":"O'Reilly","year":"2017","journal-title":"J Clin Oncol."},{"key":"B414","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1002\/cam4.2425","article-title":"A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer","volume":"8","author":"Hu","year":"2019","journal-title":"Cancer Med."},{"key":"B415","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.trecan.2017.08.007","article-title":"New opportunities and challenges to defeat cancer stem cells","volume":"3","author":"Ramos","year":"2017","journal-title":"Trends Cancer."},{"key":"B416","doi-asserted-by":"publisher","first-page":"6024","DOI":"10.1158\/0008-5472.CAN-13-1198","article-title":"An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin","volume":"73","author":"Garner","year":"2013","journal-title":"Cancer Res."},{"key":"B417","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2217\/imt.09.23","article-title":"In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology","volume":"1","author":"Prassler","year":"2009","journal-title":"Immunotherapy."},{"key":"B418","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1186\/s12885-017-3641-6","article-title":"A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer","volume":"17","author":"Reynolds","year":"2017","journal-title":"BMC Cancer."},{"key":"B419","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00280-016-3214-4","article-title":"LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer","volume":"79","author":"Takahashi","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"key":"B420","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1080\/19420862.2016.1212147","article-title":"Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds","volume":"8","author":"Malm","year":"2016","journal-title":"mAbs."},{"key":"B421","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4081\/oncol.2018.355","article-title":"HER3 signaling and targeted therapy in cancer","volume":"12","author":"Mishra","year":"2018","journal-title":"Oncol Rev."},{"key":"B422","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","article-title":"Gantenerumab: a novel human anti-abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta","volume":"28","author":"Bohrmann","year":"2012","journal-title":"J Alzheimers Dis."},{"key":"B423","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimers Res Ther."},{"key":"B424","doi-asserted-by":"publisher","first-page":"11717","DOI":"10.1073\/pnas.1120068109","article-title":"Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors","volume":"109","author":"Gurney","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"B425","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1200\/jco.2013.31.15_suppl.2540","article-title":"First-in-human evaluation of the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway in a phase I study for patients with advanced solid tumors","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol."},{"key":"B426","doi-asserted-by":"publisher","first-page":"e1700090","DOI":"10.1126\/sciadv.1700090","article-title":"WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death","volume":"3","author":"Fischer","year":"2017","journal-title":"Sci Adv."},{"key":"B427","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4161\/mabs.28394","article-title":"A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma","volume":"6","author":"Cohen","year":"2014","journal-title":"mAbs."},{"key":"B428","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s12325-016-0287-8","article-title":"Pharmacokinetics, pharmacodynamics, and safety of MEDI4212, an anti-IgE monoclonal antibody, in subjects with atopy: a phase I study","volume":"33","author":"Sheldon","year":"2016","journal-title":"Adv Ther."},{"key":"B429","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/sj.cdd.4402306","article-title":"Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5","volume":"15","author":"Adams","year":"2008","journal-title":"Cell Death Differ."},{"key":"B430","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-09-1267","article-title":"A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies","volume":"16","author":"Camidge","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B431","doi-asserted-by":"publisher","first-page":"e18511","DOI":"10.1200\/jco.2010.28.15_suppl.e18511","article-title":"Phase II study of PRO95780 plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL)","volume":"28","author":"Wittebol","year":"2010","journal-title":"J Clin Oncol."},{"key":"B432","doi-asserted-by":"publisher","first-page":"7535","DOI":"10.1200\/jco.2010.28.15","article-title":"Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab (PCB) in non-small cell lung cancer (NSCLC)","volume":"28","author":"Karapetis","year":"2010","journal-title":"J Clin Oncol."},{"key":"B433","first-page":"3433","article-title":"Generation and characterization of LFG316, a fully-human anti-C5 antibody for the treatment of age-related macular degeneration","volume":"55","author":"Roguska","year":"2014","journal-title":"Invest Ophthalmol Visual Sci."},{"key":"B434","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3390\/ijms20071693","article-title":"Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules","volume":"20","author":"Nebbioso","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B435","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat Rev Nephrol."},{"key":"B436","author":"Ferlin","year":"2017","journal-title":"Anti-interferon Gamma Antibodies and Methods of Use Thereof"},{"key":"B437","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40265-018-1046-8","article-title":"Emapalumab: first global approval","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs."},{"key":"B438","author":"Kerschbaumer","year":"2014","journal-title":"Anti Mif Antibodies"},{"key":"B439","doi-asserted-by":"publisher","first-page":"ii105","DOI":"10.1093\/annonc\/mdw200.11","article-title":"PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil\/leucovorin (5-FU\/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)","volume":"27","author":"Mahalingam","year":"2016","journal-title":"Ann Oncol."},{"key":"B440","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/23809000.2016.1185369","article-title":"The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer","volume":"1","author":"Meyer","year":"2016","journal-title":"Expert Rev Qual Life Cancer Care."},{"key":"B441","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jcmg.2014.06.021","article-title":"FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity","volume":"8","author":"Lehrer-Graiwer","year":"2015","journal-title":"JACC Cardiovasc Imaging."},{"key":"B442","doi-asserted-by":"publisher","first-page":"e0171205","DOI":"10.1371\/journal.pone.0171205","article-title":"A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma","volume":"12","author":"Wichert","year":"2017","journal-title":"PLoS ONE."},{"key":"B443","first-page":"40","article-title":"Recombinant mAb libraries: screening for new therapeutics","volume":"23","author":"Wiles","year":"2007","journal-title":"IPT"},{"key":"B444","author":"Pettersson","year":"2019","journal-title":"Dyax Corp. New Antibodies Against Phosphorylcholine."},{"key":"B445","first-page":"A15644","article-title":"Abstract 15644: a fully human monoclonal IgG phosphorylcholine antibody prevents accelerated atherosclerosis in mice","volume":"124","author":"Pettersson","year":"2011","journal-title":"Circulation."},{"key":"B446","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1161\/CIRCRESAHA.120.315942","article-title":"Vaccination strategies and immune modulation of atherosclerosis","volume":"126","author":"Nilsson","year":"2020","journal-title":"Circ Res."},{"key":"B447","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1128\/JVI.80.2.891-899.2006","article-title":"Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies","volume":"80","author":"Zhu","year":"2006","journal-title":"J Virol."},{"key":"B448","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1086\/528801","article-title":"Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody","volume":"197","author":"Zhu","year":"2008","journal-title":"J Infect Dis."},{"key":"B449","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(19)30634-6","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study","author":"Playford","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"B450","doi-asserted-by":"publisher","first-page":"523","DOI":"10.4161\/mabs.27398","article-title":"ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade","volume":"6","author":"Silence","year":"2014","journal-title":"mAbs."},{"key":"B451","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2015.1046648","article-title":"Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform","volume":"7","author":"Klarenbeek","year":"2015","journal-title":"mAbs."},{"key":"B452","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.M210665200","article-title":"The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity","volume":"278","author":"Shinkawa","year":"2003","journal-title":"J Biol Chem."},{"key":"B453","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1182\/blood-2018-99-118302","article-title":"Argx-110 targeting CD70, in combination with azacitidine, shows favorable safety profile and promising anti-leukemia activity in newly diagnosed AML patients in an ongoing phase 1\/2 clinical trial","volume":"132","author":"Ochsenbein","year":"2018","journal-title":"Blood."},{"key":"B454","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-17-0613","article-title":"Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies","volume":"23","author":"Aftimos","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B455","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1172\/JCI72316","article-title":"Four individually druggable MET hotspots mediate HGF-driven tumor progression","volume":"124","author":"Basilico","year":"2014","journal-title":"J Clin Invest."},{"key":"B456","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1158\/0008-5472.CAN-15-0356","article-title":"Depleting MET-expressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF\/MET signaling","volume":"75","author":"Hultberg","year":"2015","journal-title":"Cancer Res."},{"key":"B457","doi-asserted-by":"publisher","first-page":"18709","DOI":"10.1073\/pnas.0606304103","article-title":"Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies","volume":"103","author":"Vaccaro","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B458","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1200\/jco.2015.33.15_suppl.2580","article-title":"A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors","volume":"33","author":"Aftimos","year":"2015","journal-title":"J Clin Oncol."},{"key":"B459","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda","year":"2016","journal-title":"BioDrugs."},{"key":"B460","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","article-title":"Next generation antibody drugs: pursuit of the \u2018high-hanging fruit\u2019","volume":"17","author":"Carter","year":"2018","journal-title":"Nat Rev Drug Discov."},{"key":"B461","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","article-title":"Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up","volume":"305","author":"Bartelds","year":"2011","journal-title":"JAMA."},{"key":"B462","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med."},{"key":"B463","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet."},{"key":"B464","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med."},{"key":"B465","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"B466","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet."},{"key":"B467","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11864-016-0409-1","article-title":"Merkel cell carcinoma therapeutic update","volume":"17","author":"Cassler","year":"2016","journal-title":"Curr Treat Opt Oncol."},{"key":"B468","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front Pharmacol."},{"key":"B469","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet."},{"key":"B470","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol."},{"key":"B471","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","article-title":"Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial","volume":"18","author":"Gulley","year":"2017","journal-title":"Lancet Oncol."},{"key":"B472","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol."},{"key":"B473","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1200\/JCO.2016.34.15_suppl.3055","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial","volume":"34","author":"Kelly","year":"2016","journal-title":"J Clin Oncol"},{"key":"B474","doi-asserted-by":"publisher","first-page":"S717","DOI":"10.1016\/S0959-8049(16)31938-4","article-title":"16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)","volume":"51","author":"Besse","year":"2015","journal-title":"Eur J Cancer."},{"key":"B475","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.1200\/jco.2015.33.15_suppl.8029","article-title":"Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study","volume":"33","author":"Horn","year":"2015","journal-title":"J Clin Oncol."},{"key":"B476","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1200\/jco.2015.33.15_suppl.8028","article-title":"Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1\u2013selected patients with non-small cell lung cancer (NSCLC)","volume":"33","author":"Spigel","year":"2015","journal-title":"J Clin Oncol."},{"key":"B477","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1200\/jco.2015.33.15_suppl.4501","article-title":"A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC)","volume":"33","author":"Petrylak","year":"2015","journal-title":"J Clin Oncol."},{"key":"B478","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-018-2955-9","article-title":"Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma","volume":"140","author":"Lukas","year":"2018","journal-title":"J Neurooncol."},{"key":"B479","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1200\/JCO.2015.63.7421","article-title":"Atezolizumab, an anti\u2013programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study","volume":"34","author":"McDermott","year":"2016","journal-title":"J Clin Oncol."},{"key":"B480","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1038\/cti.2016.27","article-title":"A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses","volume":"5","author":"Grenga","year":"2016","journal-title":"Clin Transl Immunol."},{"key":"B481","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","article-title":"Antibody-dependent cellular cytotoxicity activity of a novel anti\u2013PD-L1 antibody avelumab (MSB0010718C) on human tumor cells","volume":"3","author":"Boyerinas","year":"2015","journal-title":"Cancer Immunol Res."},{"key":"B482","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol."},{"key":"B483","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s40265-017-0825-y","article-title":"Tivozanib: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs."},{"key":"B484","doi-asserted-by":"publisher","first-page":"31","DOI":"10.46582\/jsrm.0101005","article-title":"Immunotoxins: a review of their use in cancer treatment","volume":"1","author":"Aruna","year":"2006","journal-title":"J Stem Cells Regen Med."},{"key":"B485","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","article-title":"CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies","volume":"15","author":"Alderson","year":"2009","journal-title":"Clin Cancer Res."},{"key":"B486","first-page":"995","article-title":"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display","volume":"8","author":"Salvatore","year":"2002","journal-title":"Clin Cancer Res."},{"key":"B487","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin."},{"key":"B488","first-page":"458","article-title":"Hairy cell leukemia: clinical presentation and follow-up of 211 patients","volume":"11","author":"Flandrin","year":"1984","journal-title":"Semin Oncol."},{"key":"B489","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol."},{"key":"B490","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1634\/theoncologist.2019-0370","article-title":"Contextualizing the use of moxetumomab pasudotox in the treatment of relapsed or refractory hairy cell leukemia","volume":"25","author":"Kreitman","year":"2020","journal-title":"Oncologist."},{"key":"B491","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.yexcr.2008.10.008","article-title":"Interaction of antibodies with ErbB receptor extracellular regions","volume":"315","author":"Schmitz","year":"2009","journal-title":"Exp Cell Res."},{"key":"B492","doi-asserted-by":"publisher","first-page":"19665","DOI":"10.1074\/jbc.M500815200","article-title":"A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity","volume":"280","author":"Lu","year":"2005","journal-title":"J Biol Chem."},{"key":"B493","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/1389450053765879","article-title":"The ErbB receptors and their ligands in cancer: an overview","volume":"6","author":"Normanno","year":"2005","journal-title":"Curr Drug Targets."},{"key":"B494","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1517\/14728222.2011.648617","article-title":"Targeting the EGFR signaling pathway in cancer therapy","volume":"16","author":"Seshacharyulu","year":"2012","journal-title":"Expert Opin Ther Targets."},{"key":"B495","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.23282","article-title":"Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer","volume":"112","author":"Hirsch","year":"2008","journal-title":"Cancer."},{"key":"B496","first-page":"2379","article-title":"Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung","volume":"53","author":"Rusch","year":"1993","journal-title":"Cancer Res."},{"key":"B497","first-page":"119","article-title":"Portrazza (Necitumumab), an IgG1 monoclonal antibody, FDA approved for advanced squamous non-small-cell lung cancer","volume":"9","author":"Fala","year":"2016","journal-title":"Am Health Drug Benefits."},{"key":"B498","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol."},{"key":"B499","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.clim.2009.01.002","article-title":"Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor","volume":"131","author":"Kaymakcalan","year":"2009","journal-title":"Clin Immunol."},{"key":"B500","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1056\/NEJM199606273342607","article-title":"The tumor necrosis factor ligand and receptor families","volume":"334","author":"Bazzoni","year":"1996","journal-title":"N Engl J Med."},{"key":"B501","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2147\/IDR.S47305","article-title":"Raxibacumab: potential role in the treatment of inhalational anthrax","volume":"7","author":"Kummerfeldt","year":"2014","journal-title":"Infect Drug Resist."},{"key":"B502","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/S0014-5793(02)03609-8","article-title":"Anthrax toxin: a tripartite lethal combination","volume":"531","author":"Ascenzi","year":"2002","journal-title":"FEBS Lett."},{"key":"B503","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4161\/mabs.3.6.17621","article-title":"Antibodies for biodefense","volume":"3","author":"Froude","year":"2011","journal-title":"mAbs."},{"key":"B504","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"JAMA."},{"key":"B505","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.tim.2014.02.012","article-title":"Anthrax lethal and edema toxins in anthrax pathogenesis","volume":"22","author":"Liu","year":"2014","journal-title":"Trends Microbiol."},{"key":"B506","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1056\/NEJMoa0810603","article-title":"Raxibacumab for the treatment of inhalational anthrax","volume":"361","author":"Migone","year":"2009","journal-title":"N Engl J Med."},{"key":"B507","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","article-title":"Belimumab: a review in systemic lupus erythematosus","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs."},{"key":"B508","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J Clin Invest."},{"key":"B509","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1084\/jem.20030789","article-title":"Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells","volume":"198","author":"Gorelik","year":"2003","journal-title":"J Exp Med."},{"key":"B510","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/path.1533","article-title":"Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome","volume":"202","author":"Lavie","year":"2004","journal-title":"J Pathol."},{"key":"B511","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1182\/blood.V97.1.198","article-title":"Synthesis and release of B-lymphocyte stimulator from myeloid cells","volume":"97","author":"Nardelli","year":"2001","journal-title":"Blood."},{"key":"B512","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1182\/blood-2002-02-0558","article-title":"Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival","volume":"100","author":"Novak","year":"2002","journal-title":"Blood."},{"key":"B513","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1084\/jem.20021343","article-title":"G-CSF-stimulated neutrophils are a prominent source of functional BLyS","volume":"197","author":"Scapini","year":"2003","journal-title":"J Exp Med."},{"key":"B514","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1021\/bi048227k","article-title":"Selectivity of BAFF\/BLyS and APRIL for binding to the TNF family receptors BAFFR\/BR3 and BCMA","volume":"44","author":"Day","year":"2005","journal-title":"Biochemistry."},{"key":"B515","doi-asserted-by":"publisher","first-page":"iii34","DOI":"10.1136\/ard.2006.058412","article-title":"The BLyS\/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity","volume":"65","author":"Cancro","year":"2006","journal-title":"Ann Rheum Dis."},{"key":"B516","first-page":"491","article-title":"BLyS levels in sera of patients with systemic lupus erythematosus: clinical and serological correlation","volume":"16","author":"Elbirt","year":"2014","journal-title":"Isr Med Assoc J."},{"key":"B517","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","article-title":"Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study","volume":"62","author":"Jacobi","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B518","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.amjmed.2011.09.010","article-title":"B-cell-depleting therapy in systemic lupus erythematosus","volume":"125","author":"Ramos-Casals","year":"2012","journal-title":"Am J Med."},{"key":"B519","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s40265-014-0244-2","article-title":"Ramucirumab: first global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs."},{"key":"B520","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-09-2797","article-title":"Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers","volume":"16","author":"Smith","year":"2010","journal-title":"Clin Cancer Res."},{"key":"B521","doi-asserted-by":"publisher","first-page":"e80292","DOI":"10.1371\/journal.pone.0080292","article-title":"Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung","volume":"8","author":"Holzer","year":"2013","journal-title":"PLoS ONE."},{"key":"B522","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","article-title":"FDA approval summary: ramucirumab for gastric cancer","volume":"21","author":"Casak","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B523","first-page":"49","article-title":"Cyramza (Ramucirumab) approved for the treatment of advanced gastric cancer and metastatic non-small-cell lung cancer","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits."},{"key":"B524","first-page":"46","article-title":"Options for second-line treatment in metastatic colorectal cancer","volume":"14","author":"Lee","year":"2016","journal-title":"Clin Adv Hematol Oncol."},{"key":"B525","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40265-020-01263-6","article-title":"Ramucirumab: a review in hepatocellular carcinoma","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs."},{"key":"B526","doi-asserted-by":"publisher","first-page":"212594","DOI":"10.7573\/dic.212594","article-title":"Guselkumab for the treatment of psoriasis\u2013evidence to date","volume":"8","author":"Nogueira","year":"2019","journal-title":"Drugs Context."},{"key":"B527","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1365-2567.2005.02257.x","article-title":"The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects","volume":"117","author":"Shimozato","year":"2006","journal-title":"Immunology."},{"key":"B528","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology."},{"key":"B529","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","article-title":"The role of IL 23 in the treatment of psoriasis","volume":"13","author":"Puig","year":"2017","journal-title":"Expert Rev Clin Immunol."},{"key":"B530","doi-asserted-by":"publisher","first-page":"104ra0","DOI":"10.1126\/scitranslmed.3002949","article-title":"Human TH17 cells are long-lived effector memory cells","volume":"3","author":"Kryczek","year":"2011","journal-title":"Sci Transl Med."},{"key":"B531","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet."},{"key":"B532","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet."},{"key":"B533","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41584-020-0420-6","article-title":"IL-23 inhibitor guselkumab shows promise for PsA","volume":"16","author":"McHugh","year":"2020","journal-title":"Nat Rev Rheumatol."},{"key":"B534","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12959-015-0048-y","article-title":"Contact pathway of coagulation and inflammation","volume":"13","author":"Wu","year":"2015","journal-title":"Thromb J."},{"key":"B535","doi-asserted-by":"publisher","first-page":"3819","DOI":"10.1182\/blood.V90.10.3819","article-title":"Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes","volume":"90","author":"Colman","year":"1997","journal-title":"Blood."},{"key":"B536","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/cea.12293","article-title":"High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency","volume":"44","author":"Suffritti","year":"2014","journal-title":"Clin Exp Allergy."},{"key":"B537","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/01.CIR.95.5.1115","article-title":"Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans","volume":"95","author":"Hornig","year":"1997","journal-title":"Circulation."},{"key":"B538","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.iac.2017.04.001","article-title":"Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade","volume":"37","author":"Kaplan","year":"2017","journal-title":"Immunol Allergy Clin North Am."},{"key":"B539","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1016\/j.molimm.2008.05.007","article-title":"Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates","volume":"45","author":"Pappalardo","year":"2008","journal-title":"Mol Immunol."},{"key":"B540","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.bbrc.2006.03.092","article-title":"Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor","volume":"343","author":"Dewald","year":"2006","journal-title":"Biochem Biophys Res Commun."},{"key":"B541","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.anai.2014.05.028","article-title":"A phase 1 study investigating DX-2930 in healthy subjects","volume":"113","author":"Chyung","year":"2014","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B542","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1605767","article-title":"Inhibiting plasma kallikrein for hereditary angioedema prophylaxis","volume":"376","author":"Banerji","year":"2017","journal-title":"N Engl J Med."},{"key":"B543","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"B544","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat Immunol."},{"key":"B545","doi-asserted-by":"publisher","first-page":"e1003905","DOI":"10.1371\/journal.ppat.1003905","article-title":"Tailored immune responses: novel effector helper T cell subsets in protective immunity","volume":"10","author":"Kara","year":"2014","journal-title":"PLoS Pathog."},{"key":"B546","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B547","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12659\/PJR.883763","article-title":"Psoriatic arthritis","volume":"78","author":"Sankowski","year":"2013","journal-title":"Pol J Radiol."},{"key":"B548","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"van der Fits","year":"2009","journal-title":"J Immunol."},{"key":"B549","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/j.0022-202X.2004.22607.x","article-title":"Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population","volume":"122","author":"Sagoo","year":"2004","journal-title":"J Invest Dermatol."},{"key":"B550","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1086\/377159","article-title":"The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs","volume":"73","year":"2003","journal-title":"Am J Hum Genet."},{"key":"B551","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/acr.20496","article-title":"Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis","volume":"63","author":"Eder","year":"2011","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"B552","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B553","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B554","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.15242","article-title":"Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials","volume":"33","author":"Langley","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B555","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos","year":"2012","journal-title":"Angiogenesis."},{"key":"B556","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer."},{"key":"B557","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/pr.2015.15","article-title":"VEGF mRNA and protein concentrations in the developing human eye","volume":"77","author":"Ma","year":"2015","journal-title":"Pediatr Res."},{"key":"B558","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1097\/IAE.0b013e318134eecd","article-title":"Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits","volume":"27","author":"Gaudreault","year":"2007","journal-title":"Retina."},{"key":"B559","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1016\/j.ophtha.2007.09.012","article-title":"Pharmacokinetics of intravitreal ranibizumab (Lucentis)","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology."},{"key":"B560","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers."},{"key":"B561","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1365-2141.2004.05217.x","article-title":"von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura","volume":"127","author":"Peyvandi","year":"2004","journal-title":"Br J Haematol."},{"key":"B562","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med."},{"key":"B563","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood."},{"key":"B564","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","article-title":"Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis","volume":"127","author":"Das","year":"2016","journal-title":"Blood."},{"key":"B565","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","article-title":"Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections","volume":"3","author":"Lounder","year":"2019","journal-title":"Blood Adv."},{"key":"B566","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","article-title":"Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation","volume":"100","author":"Henter","year":"2002","journal-title":"Blood."},{"key":"B567","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1136\/adc.27.136.519","article-title":"Familial haemophagocytic reticulosis","volume":"27","author":"Farquhar","year":"1952","journal-title":"Arch Dis Child."},{"key":"B568","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41409-019-0562-9","volume":"54","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"B569","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J Biomed Sci."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:34:59Z","timestamp":1696595699000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.01986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":569,"alternative-id":["10.3389\/fimmu.2020.01986"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.01986","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,28]]},"article-number":"1986"}}